Updated to include new data up to 21 March. Updated to include new data up to 28 March 2021. Updated to include new data up to 5 April 2021. We have uploaded the updated weekly summary of Yellow Card reporting on Coronavirus vaccines' ADRs Updated to include new data up to 21 April 2021. Updated to include new data up to 28 April 2021. Updated to include new data up to 2 June 2021. New weekly summary of Yellow Card reporting for Coronavirus Vaccines with data until 9 June 2021 Updated to include new data up to 16 June 2021. Updated to include new data up to 23 June 2021. Updates for ADR's summary up to 30 June 2021.
Updated weekly report published with figures up to and including 14 July Updated report with figures up to and including 21 July Updated with figures for up to 28 July 2021 Updated the report to include information up to and including 11 August Updated the ADR report with figures up to and including 18 August. Updated the weekly ADR report to cover the period from 9 December 2020 to 25 August 2021. Updated the ADR report to include data up to 1 September 2021 Updated the report to include data up to and including 8 September 2021. Updated figures up to and including 15 September Updates to the weekly summary of adverse reactions.
#Worst side effect of covid vaccine update
Updated with figures up to 6 October 2021Ī weekly update covering adverse reactions to approved COVID-19 vaccines. Updated to include reports up to and including 13 October Weekly report updated to include data up to and including 20 October 2021 Weekly update to adverse reactions to COVID-19 vaccines. Updated with figures up to and including 3 November 2021 Updated with figures up to and including 10 November 2021 Summary of Yellow Card reporting updated to include figures up to and including 17 nov Updated to include data up to 1 December 2021 Updated to include figures up to 8 December 2021 Updated to include data up to 15 December Updated the report to include data up to and including 22 December 2021. Updated to include data up to 9 February 2022 The summary of Yellow Card reporting has been updated to reflect reports up to and including 23 February 2022. Updating the weekly report to include figures up to and including 2 March 2022. The weekly summary has been updated to include data up to 30 March.
The weekly summary has been updated to include data up to 6 April 2022. The summary has been updated to include data up to. The summary has been updated to include data up to 8 June 2022. The summary has been updated to include data up to 15 June 2022. Updated to include data up to and including 29 June 2022. Updated to include data up to and including 13 July 2022.
#Worst side effect of covid vaccine pdf
No changes were made to the PDF report and this data remains correct. On 25 July 2022, data in table 1 and 2 published on the html webpage were corrected. Updated to include data up to and including 24 August 2022.įollowing publication on 22 July 2022, inconsistencies were noted between the html and pdf versions for tables 1 and 2 of the report. The Coronavirus - Summary of Yellow Card reporting was updated to include data up to 28 September 2022. This report covers the period 9 December 2020 to 28 September 2022. This report summarises information received via the Yellow Card scheme and will be published regularly to include other safety investigations carried out by the MHRA under the COVID-19 Vaccine Surveillance Strategy.
This monitoring strategy is continuous, proactive and based on a wide range of information sources, with a dedicated team of scientists reviewing information daily to look for safety issues or unexpected rare events. This is a requirement for all authorised medicines and vaccines in the UK. The clinical trials of COVID-19 vaccines have shown them to be effective and acceptably safe however, as part of its statutory functions, the MHRA is responsible for monitoring these vaccines on an ongoing basis to ensure their benefits continue to outweigh any risks. In relation to COVID-19 vaccines, the MHRA has authorised their supply following a rigorous review of their safety, quality and efficacy. The MHRA has played an active role in responding to the coronavirus pandemic.
0 kommentar(er)
